BRC has developed a pipeline of prescription medicines based on cannabinoids addressing pain and neurological and inflammatory conditions. Two investigational products are currently being tested in clinical trials for Complex Regional Pain Syndrome (CRPS) and Aromatase Inhibitor-Induced Arthralgia (AIIA), respectively. BRC is registered with the Drug Enforcement Administration.
.
We are combining cannabinoids at ratios that are narrowly defined and predicted to maximize safety and efficacy. Our medicines are designed to ensure each patient's comfort and support their return to a life not dictated by their symptoms.
Our team consists of leaders in the pharmaceutical and regulated cannabinoid therapeutics industries. We are building a fully integrated organization, driving innovation from development to commercialization
“BRC is a mission-driven company with excellent leadership in a high growth industry, a business that is already in a significantly advantageous position given their unique ability to be fully compliant with the DEA.”
– Howard Goodwin, MD, Managing Partner,
Intrinsic Capital Partners
Two of our therapeutic candidates are currently being tested in investigator-initiated clinical trials for Complex Regional Pain Syndrome and Aromatase Inhibitor-Induced Arthralgia.
At BRC, we recognize that everyone deserves to live a life not restricted by symptoms. We have dedicated ourselves to help patients Live Every Day to the fullest.
